Mortality in French people with polyhandicap/profound intellectual and multiple disabilities
Ilyes HamoudaKarine BaumstarckMarie‐Anastasie AimAny Beltran AnzolaAnderson LoundouThierry Billette de VillemeurLaurent BoyerPascal AuquierMarie-Christine Rousseau
0
Citation
29
Reference
10
Related Paper
Abstract:
Abstract Background In recent decades, progress has been made in the care of people with polyhandicap/profound intellectual and multiple disabilities (PIMD) through a better understanding of the pathophysiology and the development of new care management and rehabilitation strategies adapted to these extreme pathologies. Although there is a lack of knowledge about the health status and care management of the oldest people, a better understanding of the natural course of life of people with polyhandicap/PIMD would consequently allow the optimisation of preventive and curative care management strategies. Few robust data on mortality and life expectancy have been documented for this population in France. Our aims are to estimate the median survival time and assess the factors associated with mortality in people with polyhandicap/PIMD receiving care in France. Methods This study included people with polyhandicap/PIMD, followed by the French national cohort ‘Eval‐PLH’ since 2015. These individuals were included in specialised rehabilitation centres and residential institutions. The people included in the first wave of the cohort (2015–2016) were eligible for the present study. Vital status on 1 January 2022 (censoring date) was collected in two ways: (1) spontaneous reporting by the participating centre to the coordinating team and (2) systematic checking on the French national death platform. According to the vital status, survival was calculated in years from the date of birth to the date of death or from the date of birth to the censoring date. The factors associated with mortality were evaluated using the Cox proportional regression hazards model. Results Data from 780 individuals aged between 3 and 67 years were analysed. At the censoring date, 176 (22.6%) had died, and the mean survival was 52.8 years (95% confidence interval: 51.1–54.5). Mortality was significantly associated with a progressive aetiology, recurrent pulmonary infections, drug‐resistant epilepsy and a higher number of medical devices. Conclusions This study shows for the first time the survival and impact of factors associated with mortality in people with polyhandicap/PIMD in France.Keywords:
Censoring (clinical trials)
This article develops randomization-based methods for times to repeated events in two-arm randomized trials with noncompliance and dependent censoring. Structural accelerated failure time models are assumed to capture causal effects on repeated event times and dependent censoring time, but the dependence structure among repeated event times and dependent censoring time is unspecified. Artificial censoring techniques to accommodate nonrandom noncompliance and dependent censoring are proposed. Estimation of the acceleration parameters are based on rank-based estimating functions. A simulation study is conducted to evaluate the performance of the developed methods. An illustration of the methods using data from an acute myeloid leukemia trial is provided.
Censoring (clinical trials)
Event data
Log-rank test
Repeated measures design
Cite
Citations (5)
This article introduces readers to survival (failure-time) models, with a focus on Kaplan-Meier curves, Cox regression and sample size estimation.An example is used to show readers how to calculate a Kaplan-Meier curve from first principles.What makes survival data unique is censoring. Readers should understand censoring before undertaking an analysis of survival data.The Cox model continues to set the standard for survival models, and will continue well into the future.
Censoring (clinical trials)
Cite
Citations (1)
Abstract The concepts of independent right censoring and noninformative right censoring in survival analysis are defined. Dependent censoring is a kind of selection bias and adds to biased inference for the survival time distribution. Informative censoring typically leads to inefficient inference. Examples are presented and relations between right censoring and competing risks are discussed. Other kinds of censoring, including interval censoring are touched upon.
Censoring (clinical trials)
Statistical Inference
Cite
Citations (0)
▪ Abstract A key characteristic that distinguishes survival analysis from other areas in statistics is that survival data are usually censored. Censoring occurs when incomplete information is available about the survival time of some individuals. We define censoring through some practical examples extracted from the literature in various fields of public health. With few exceptions, the censoring mechanisms in most observational studies are unknown and hence it is necessary to make assumptions about censoring when the common statistical methods are used to analyze censored data. In addition, we present situations in which censoring mechanisms can be ignored. The effects of the censoring assumptions are demonstrated through actual studies.
Censoring (clinical trials)
Cite
Citations (314)
Dynamic learning systems subject to selective labeling exhibit censoring, i.e. persistent negative predictions assigned to one or more subgroups of points. In applications like consumer finance, this results in groups of applicants that are persistently denied and thus never enter into the training data. In this work, we formalize censoring, demonstrate how it can arise, and highlight difficulties in detection. We consider safeguards against censoring - recourse and randomized-exploration - both of which ensure we collect labels for points that would otherwise go unobserved. The resulting techniques allow examples from censored groups to enter into the training data and correct the model. Our results highlight the otherwise unmeasured harms of censoring and demonstrate the effectiveness of mitigation strategies across a range of data generating processes.
Censoring (clinical trials)
Training set
Cite
Citations (0)
Nowadays, the use of various censorship methods has become widespread in industrial and clinical tests. Type I and Type II progressive censoring are two types of these censors. The use of these censors also has some disadvantages. This article tries to reduce the defects of the type I progressive censoring by making some change to progressive censorship. Considering the number and the time of the withdrawals as a random variable, this is done. First, Type I, Type II progressive censoring and two of their generalizations are introduced. Then, we introduce the new censoring based on the Type I progressive censoring and its probability density function. Also, some of its special cases will be explained and a few related theorems are brought. Finally, the simulation algorithm is brought and for comparison of introduced censorship against the traditional censorships a simulation study was done.
Censoring (clinical trials)
Cite
Citations (0)
ABSTRACT Censoring occurs commonly in clinical trials. This article investigates a new censoring scheme, namely, Type II progressive interval censoring with random removals to cope with the setting that patients are examined at fixed regular intervals and dropouts may occur during the study period. We discuss the maximum likelihood estimation of the model parameters and derive the corresponding asymptotic variances when survival times are assumed to be Weibull distributed. An example is discussed to illustrate the application of the results under this censoring scheme.
Censoring (clinical trials)
Interval estimation
Cite
Citations (23)
The Type-I and Type-II censoring schemes are the most prominent and commonly used censoring schemes in practice. In this work, a mixture of Type-I and Type- II censoring schemes, named the Type I-Type II mixture censoring scheme, has been introduced. Different censoring schemes have been discussed, along with their benefits and drawbacks. For the proposed censoring scheme, we analyze the data under the assumption that failure times of experimental units follow the Weibull distribution. The computational formulas for the expected number of failures and the expected failure time are provided. Maximum likelihood estimation and Bayesian estimation are used to estimate the model parameters. On the basis of thorough Monte Carlo simulations, the investigated inferential approaches are evaluated. Finally, a numerical example is provided to demonstrate the method of inference discussed here.
Censoring (clinical trials)
Cite
Citations (0)
Dynamic learning systems subject to selective labeling exhibit censoring, i.e. persistent negative predictions assigned to one or more subgroups of points. In applications like consumer finance, this results in groups of applicants that are persistently denied and thus never enter into the training data. In this work, we formalize censoring, demonstrate how it can arise, and highlight difficulties in detection. We consider safeguards against censoring – recourse and randomized-exploration – both of which ensure we collect labels for points that would otherwise go unobserved. The resulting techniques allow examples from censored groups to enter into the training data and correct the model. Our results highlight the otherwise unmeasured harms of censoring and demonstrate the effectiveness of mitigation strategies across a range of data generating processes.
Censoring (clinical trials)
Training set
Robustness
Cite
Citations (1)
Our constitution fails to provide a legal system for censoring the cases against the constitution. It is, therefore, necessary to set up one to stipulate clearly and systematically the censoring contents, procedures, mode and effectiveness as well as institutions for censoring, objects to be censored, and the way of bearing responsibilities.
Censoring (clinical trials)
Cite
Citations (0)